

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0154US1	Application No. 10/560,098
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Taro Miyazaki et al.	
		Filing Date April 28, 2006	Group Art Unit 1643
(37 CFR §1.98(b))			

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/L.B./	1	2006/0058511	03/16/2006	Tanikawa et al.			
	2	2009/0214535	08/27/2009	Igawa et al.			
	3	2009/0297501	12/03/2009	Igawa et al.			
	4	2010/0015133	01/21/2010	Igawa et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
/L.B./	5	EP 1 327 681	07/16/2003	Europe			Yes No
	6	WO 01/79494	10/25/2001	WIPO			
	7	WO 02/33072	04/25/2002	WIPO			
	8	WO 02/33073	04/25/2002	WIPO			

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/L.B./	9	ABE et al., "Surrogate thrombopoietin," <i>Immunology Letters</i> , 61:73-78 (1998)
	10	CREIGHTON, "Protein folding," <i>Biochem. J.</i> , 270(1):1-16 (1990)
	11	DENG et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis," <i>Blood</i> , 92:1981-1988 (1998)
	12	ELLIOTT et al., "Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies," <i>J. Biol. Chem.</i> , 271:24691-24697 (1996)
	13	GODING, "Monoclonal Antibodies: Principles and Practice," <i>Academic Press</i> , second Ed., 125:129 (1986)
	14	KONTERMANN, R., "Recombinant bispecific antibodies for cancer therapy," <i>Acta Pharmacol. Sin.</i> , 26(1):1-9 (2005)
	15	PALACIOS et al., "IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo," <i>Cell</i> , 41:727-734 (1985)
	16	SOUYRI, "Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin," <i>Seminars in Hematology</i> , 35(3):222-231 (1998)
	17	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 15, 2009 in U.S. App. Ser. No. 10/551,504, filed August 14, 2009, 19 pages
	18	International Search Report for App. Ser. No. PCT/JP2004/008585, mailed September 7, 2004, 4 pages
	19	International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/008585, 10 pages

Examiner Signature /Lynn Bristol/	Date Considered 05/27/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0154US1	Application No. 10/560,098
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Taro Miyazaki et al.	
		Filing Date April 28, 2006	Group Art Unit 1643
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/L.B./	20	European Search Report for App. Ser. No. EP 06 73 0748, dated April 22, 2009, 7 pages
/L.B./	21	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed January 7, 2010, 13 pages

Examiner Signature /Lynn Bristol/	Date Considered 05/27/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	